Radiopharm Theranostics Advances Phase 1 Trial for 177Lu-RAD204

The latest announcement is out from Radiopharm Theranostics Limited ( (AU:RAD) ).

Radiopharm Theranostics has announced a significant advancement in its Phase 1 clinical trial for 177Lu-RAD204, a radiotherapeutic asset targeting PD-L1 positive advanced cancers. The Data Safety and Monitoring Committee has approved the continuation of the trial without modifications, allowing the company to proceed to a higher dose cohort. This development is expected to accelerate enrollment and expand the trial to include multiple tumor types, potentially enhancing clinical outcomes for patients with these cancers.

More about Radiopharm Theranostics Limited

Radiopharm Theranostics is a clinical-stage radiotherapeutics company that develops innovative radiopharmaceutical products for diagnostic and therapeutic applications, particularly in oncology. The company is listed on both the ASX and NASDAQ and has a diverse pipeline of technologies including peptides, small molecules, and monoclonal antibodies targeting various solid tumor cancers.

Average Trading Volume: 6,074,363

Technical Sentiment Signal: Sell

Current Market Cap: A$50.18M

For detailed information about RAD stock, go to TipRanks’ Stock Analysis page.